Korzyci wykraczaj poza sam redukcj wagi, obejmujc popraw kontroli cukrzycy, profilu lipidowego i obnienie cinienia
Clinicians should recognize ischemic colitis as a possible, though rare, adverse effect of GLP-1/GIP agonists
to reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression
The FDA defines biosimilar interchangeability as requiring a higher standard than mere similarity: an interchangeable biosimilar must produce the same clinical result as the reference product in any given patient, and for products administered more than once, the risk of switching must be no greater than continuing on the reference product
Schedule 1 weekly subQ shot for retatrutide